Colorectal carcinoma

Title Study Year Journal/Event
Dermatux: Phase IV trial of C-FOLFIRI in 1st-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski CC, Staib F, Goehler T, Hebart HF, Neise M, Rudi J, et al. J Clin Oncol 2016;34(suppl; abstr e15048).

DERMATUX 2016 ASCO
Quality of Life assessment in patients with metastatic colorectal cancer (mCRC) receiving maintenance therapy after first-line induction treatment: A preplanned analysis of the phase III AIO KRK 0207 trial.

Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller C, Killing B, Depenbusch R, et al. Ann Oncol. 2016;27(12):2203–10.

AIO KRK 0207 2016 Ann Oncol
Behandlungsrealität von Patienten mit metastasiertem kolorektalem Karzinom nach (K)RAS Mutationsstatus – Daten aus dem klinischen Tumorregister Kolorektales Karzinom (TKK).

Zahn M-O, Schnell R, Karcher A, Schnitzler M, Wetzel N, Fleitz A, et al.Oncol Res Treat. 2016;39 (suppl5)(V171)

TKK 2016 DGHO
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens C-C, et al. Lancet Oncol. 2015 Oct;16(13):1355–69.

AIO KRK 0207 2015 Lancet
Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – results from a prospective cohort study.

Marschner N, Arnold D, Engel E, Hutschenreuter U, Rauh J, Freier W, et al. Clin Epidemiol. 2015;7:295–303.

TKK 2015 Clin Epidemiol.
Implementation of RAS testing in patients with metastatic colorectal cancer in German outpatient cancer centers – data from the clinical TKK registry.

Schnell R, Trarbach T, Broszeit-Luft S, Musch R, Frank M, Kopfmann S, et al. Oncol Res Treat. 2015;38 (suppl 5)(V394):113.

TKK 2015 DGHO
Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – results from a prospective cohort study

Marschner N, Arnold D, Engel E, Hutschenreuter U, Rauh J, Freier W, u. a. accepted at Clin Epidemi. 2014

TKK 2014 Clin Epidemi
A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.

Goehler T, Woerns MA, Hebart HF, Heike M, Neise M, Rudi J, et al. J Clin Oncol. 2014;32(suppl; abstr e20724).

DERMATUX 2014 ASCO
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper S, Moehler M, Hegewisch-Becker S, Overkamp F, Bechstein WO, Kullmann F, et al. J Clin Oncol. 2014;32:5s(suppl; abstr TPS3658).

LICC 2014 ASCO
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study.

Hegewisch-Becker S, Arnold D, Lerchenmüller C, Killing B, Depenbusch R, Steffens C, et al. Oncol Res Treat. 2014;37 (suppl.5)(V327):99.

AIO KRK 0207 2014 DGHO
Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer – data from the clinical TKK registry;

Schnell, R., Broszeit-Luft S., Musch R., Harde J., Kopfmann S., Jänicke M., Marschner N. for the TKK registry group; OncolResTreat 2014; 37(suppl.5)(V332)

 

TKK 2014 DGHO
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper S, Overkamp F, Moehler M, Kullmann F, Lang H, Schoen M, u. a. J Clin Oncol. 2013;31(suppl; abstr TPS3124^).

LICC 2013 ASCO
Prognostic stratification and survival of patients with metastatic colorectal cancer: results from a prospective study.

Marschner N, Karcher A, Ladda E, Franzem M, Jänicke M. ECCO. 2013;2256.

TKK 2013 ESMO
A prognostic score based on tumour characteristics to predict survival of patients with metastatic colorectal cancer: results from a prospective study.

Marschner N, Karcher A, Ladda E, Franzem M, Jänicke M. Onkologie. 2013;(V391).

TKK 2013 DGHO
Treatment of younger and elderly colorectal cancer patients in German outpatient centres – data from the clinical TKK registry.

Freier W, Groschek M, Schröder J, von Verschuer U, Jänicke M, Marschner N. Onkologie. 2012;35 (Suppl.6)(P193):51.

TKK 2012 DGHO
Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?

Hartmann, H., Müller, J., & Marschner, N. (2012). Journal of clinical oncology, 30(26), 3317–3318. doi:10.1200/JCO.2012.43.3409

TKK 2012 J Clin Oncol
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Schimanski CC, Moehler MH, Lang H, Schoen M, Smith-Machnow V, Kanzler S, u. a. 2012;(Abstract 99605).

LICC 2012 ASCO
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases–a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Schimanski CC, Mohler M, Schon M, van Cutsem E, Greil R, Bechstein WO, u. a. BMC cancer. 2012 Apr 11;12(1):144

LICC 2012 BMC Cancer
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt F, Lindauer A, Kinzig M, Strumberg D, Scheulen ME, Mross K, u. a. Int J Clin Pharmacol Ther. 2011 Jan;49(1):88–90.

Cesar-C-II-005 2011 Int J Clin Pharmacol Ther
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.

Mross K, Büchert M, Fasol U, Jaehde U, Kanefendt F, Strumberg D, u. a. Int J Clin Pharmacol Ther. 2011 Jan;49(1):96–8.

Cesar-C-II-005 2011 Int J Clin Pharmacol Ther
Survival and palliative treatment course of colorectal cancer patients in German outpatient centres. Data from the clinical registry – TKK Registry.

Freier W, Rauh J, Kindler M, Jänicke M, Marschner N. Onkologie. 2011;34 (Suppl.6)(Vortrag V643):189.

TKK 2011 DGHO
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases – A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial.

Freier W, Rauh J, Kindler M, Jänicke M, Marschner N. J Clin Oncol. 2011;29 (suppl)(Abstract TPS166).

LICC 2011 ASCO
The pattern of metastases in colorectal cancer. Data from a clinical registry.

Freier W, Rauh J, Hutzschenreuter U, Tessen HW, Hartmann H, Marschner N. Onkologie. 2010;33, Sup. 6:175.

TKK 2010 DGHO
The treatment of colorectal cancer in German outpatient centres. Data from a clinical registry. A joint project of the AIO and the AKS.

Freier W, Schröder J, Rauh J, Harich H-D, Hartmann H. Onkologie. 2009;32 (suppl 4):47.

TKK 2009 DGHO
Colon Registry: Influence of comorbidity on the choice of chemotherapeutic treatment. A joint project of the AIO and the AKS.

Freier W, Arnold D, Otremba B, Marschner N. Onkologie. 2008;31 (suppl 4):109.

TKK 2008 DGHO
Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.

Twelves, C. J. (2006). Clinical Colorectal Cancer, 6(4), 278–287.

X-ACT 2006 Clin Colorectal Cancer
Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea. Results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC).

Karthaus M, Ballo H, Steinmetz T, Geer T, Schimke J, Braumann D, u. a. 2005.

BUC-37/CID 2005 ASCO
Capecitabine as adjuvant treatment for stage III colon cancer.

Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., u. a. (2005). The New England Journal of Medicine, 352(26), 2696–704. doi:10.1056/NEJMoa043116

X-ACT 2005 N Engl J Med
Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer.

Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J, u. a. Oncology. 2005;68(4-6):326–32.

BUC-37/CID 2003 ASCO
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., u. a. (2003). Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 14(12), 1735–1743.

X-ACT 2003 Ann Oncol

Merken

iOMEDICO AG
Hanferstraße 28
D-79108 Freiburg

Phone: 0761 - 15 242 0
E-Mail: info@iomedico.com